🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

At Incyte, our people make us who we are. We work hard to build a culture where different perspectives are valued, and everyone has a voice. We're proud to be named a Global Most Loved Workplace by Newsweek! #IncyteProud #SolveOn

Join us at the ASCO Annual Meeting to explore how Incyte is advancing innovative approaches for patients with cancer. #ASCO25

We’re headed to the European Hematology Association Congress where we will be presenting data from our oncology portfolio. Read our press release to learn more. #EHA2025

We're sharing new data at the European Hematology Association Congress, including the first clinical data on our first-in-class targeted monoclonal antibody in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs). Stay tuned for updates at #EHA2025.

We’re looking forward to the European Hematology Association Congress this weekend, where we will present the latest findings from our hematology/oncology portfolio. Learn more. #EHA2025

#News: The Lancet has published data from the Phase 3 POD1UM-303 trial evaluating our treatment for patients with squamous cell anal carcinoma (SCAC). Read the press release to learn more.

It's day two of #EHA2025! Check out our booth and the latest from the meeting.

We’re learning about the advancements being made for patients with various hematologic conditions at #EHA2025.

Learn more about the positive data we shared on our novel, first-in-class mutant calreticulin (mutCALR) targeted monoclonal antibody in patients with essential thrombocythemia (ET) at the European Hematology Association Congress. #EHA2025 investor.incyte.com/news-releases/…

We’ve announced a global partnership with QIAGEN to develop a multimodal next generation sequencing (NGS) companion diagnostic to support our portfolio of investigational medicines for MPNs, including our novel, first-in-class, mutCALR-targeted monoclonal antibody, INCA033989.

Positive data for our novel, first-in-class mutant CALR-targeted therapy in patients with essential thrombocythemia (ET) were presented at the European Hematology Association Congress. #EHA2025

Mutations in the calreticulin gene (mutCALR) drive around 25% of all cases of essential thrombocythemia (ET), a type of myeloproliferative neoplasm (MPN). Learn more about mutCALR and how we’re targeting it in patients with ET. #EHA2025

The U.S. FDA has approved an immunotherapy combination for adult patients with follicular lymphoma (FL), bringing a new chemo-free option in the second-line setting. We’re proud to help advance care for the FL community.

Learn more from Hervé Hoppenot, our President and CEO, on the potential impact of the U.S. FDA's approval of our new treatment for adult patients with follicular lymphoma (FL).